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RESULTS  Outcome 
Median follow up was 45.3 months. 
There was a median overall survival of 29 months (95% 
confidence interval 14.4-43.8 months). 
No variable was statistically significant on univariate or 
multivariate analysis, with no difference between radiation 
doses, although this is limited by small numbers.
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INTRODUCTION 
PORT for NSCLC remains controversial [1]. However, PORT is recommended following an incomplete surgical resection 
[2]. In our centre regimes of 45 - 50Gy have been used, with the higher dose used as practice evolved. 
This audit reviews all patients treated with PORT between 2010 - 15.
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CONCLUSIONS 
¥ This single centre audit describes the outcomes of patients treated with PORT for incompletely resected NSCLC at a large 
UK teaching hospital, representing the current standard of care. 
¥ Encouragingly these outcomes are comparable to those recently reported internationally with documented median OS of 
23.8 months [3], 3-year OS rates of 34.1-49.3% [3,4], and 5-year OS rates of 32.0% [5], although comparison is limited 
due to size. 
¥ This suggests that PORT use in routine practice is promising for patients with incompletely resected NSCLC. 
¥ However, randomised trials using modern radiotherapy techniques such as LUNGART [6] are required to identify other 
subgroups who may benefit.
METHODS 
Case notes and radiotherapy records for all patients receiving PORT were retrospectively reviewed. Basic patient 
demographics, tumour characteristics, radiotherapy and survival data were collected. Descriptive statistical analysis and Cox 
regression analysis were performed using SPSS. Survival was calculated from date of diagnosis to date of death or last 
follow up.
RESULTS - Demographics 
54 patients received PORT. 
Chemotherapy was used in 29%, of whom 87% had stage 
III/IV disease. 
37% received 45Gy/20# and 63% received 50Gy/20#.
Demographic Number of patients
Gender Male 
Female
30 
24
Age Median 67
Performance  
Status
0 
1 
2 
Unknown
15 
22 
2 
15
Site of Primary Central 
Right 
Left
5 
29 
20
Histology Squamous Cell 
Adenocarcinoma 
Other histology
29 
21 
4
Stage 
(TNM v7)
1 
2 
3 
4
8 
20 
25 
1
PET performed? Yes 
No
52 
0
Surgical procedure Wedge excision 
Lobectomy 
Pneumonectomy 
Unknown
7 
35 
9 
3
1 Year OS = 76.7%

2 Year OS = 56.3%

3 Year OS = 44.7%

4 Year OS = 34.8%

5 Year OS = 30.4%

